Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Method of treating an ocular condition by administering a humanized monoclonal antibodies that target VE-PTP (HPTP-Beta)

Method of treating an ocular condition by administering a humanized monoclonal antibodies that target VE-PTP (HPTP-Beta)

US Patent 12145986 · Granted Nov 19, 2024

Estimated economic value: $27,725,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Method of treating an ocular condition by administering multispecific antibodies2025
Methods of treating intraocular pressure with activators of Tie-22024
Compositions, formulations and methods for treating ocular diseases2024
Tie-2 activators targeting the Schlemm's canal2024
Methods for treating vascular leak syndrome and cancer2024
Method of treating ocular conditions by administering an antibody that activates2024
Antibodies that bind human protein tyrosine phosphatase beta (HPTPbeta) and uses2023
Methods of treating intraocular pressure with activators of Tie-22023
Formulations of Tie-2 activators and methods of use thereof2022
Tie-2 activators targeting the Schlemm's canal2022
Humanized monoclonal antibodies that target VE-PTP (HPTP-beta)2021
Humanized monoclonal antibodies that target VE-PTP (HPTP-beta)2021